S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
This Stock Could Go Up 66% or More. (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
Is NVIDIA Leading a "Magnificent Seven Bubble"? (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
KB Home Price Weakness is a Signal to Buy this Cash Machine

Immunovant (IMVT) Stock Forecast, Price & News

$20.39
-0.86 (-4.05%)
(As of 09/22/2023 ET)
Compare
Today's Range
$20.11
$21.52
50-Day Range
$19.59
$24.94
52-Week Range
$4.26
$25.13
Volume
2.16 million shs
Average Volume
1.10 million shs
Market Capitalization
$2.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.92

Immunovant MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
36.9% Upside
$27.92 Price Target
Short Interest
Bearish
9.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Immunovant in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$6.46 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.91) to ($1.90) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

393rd out of 965 stocks

Biological Products, Except Diagnostic Industry

57th out of 161 stocks


IMVT stock logo

About Immunovant (NASDAQ:IMVT) Stock

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT Price History

IMVT Stock News Headlines

Traders Buy High Volume of Immunovant Put Options (NASDAQ:IMVT)
Immunovant Unusual Options Activity
30 Days of MarketBeat All Access Free
Access our premier stock research platform that includes research tools, stock screeners, instant alerts, real-time news and much more.
LifeSci Capital Reaffirms Their Buy Rating on Immunovant (IMVT)
What 11 Analyst Ratings Have To Say About Immunovant
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
H.C. Wainwright Remains a Buy on Immunovant (IMVT)
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
Immunovant (NASDAQ: IMVT)
Immunovant (IMVT) Gets a Buy from Stifel Nicolaus
H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT)
Immunovant (IMVT) Receives a Buy from LifeSci Capital
IMVT - Immunovant, Inc.
H.C. Wainwright Keeps Their Buy Rating on Immunovant (IMVT)
See More Headlines
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

IMVT Company Calendar

Last Earnings
8/10/2023
Today
9/23/2023
Next Earnings (Estimated)
11/03/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.92
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+36.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

Net Income
$-210,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.78 per share

Miscellaneous

Free Float
124,400,000
Market Cap
$2.66 billion
Optionable
Not Optionable
Beta
0.91
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Frank M. Torti M.B.A. (Age 44)
    M.D., MBA, Exec. Chairperson of the Board
    Comp: $92.5k
  • Dr. Peter  Salzmann M.B.A.Dr. Peter Salzmann M.B.A. (Age 55)
    M.D., CEO & Director
    Comp: $1.02M
  • Ms. Eva Renee Barnett M.B.A. (Age 43)
    Chief Financial Officer
    Comp: $871.07k
  • Dr. William L. Macias M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $719.88k
  • Dr. Jay S. Stout Ph.D. (Age 60)
    Chief Technology Officer
  • Dr. Chau Cheng M.B.A.
    Ph.D., VP of Investor Relations
  • Mr. Mark S. Levine (Age 50)
    Chief Legal Officer & Corp. Sec.
  • Ms. Lauren Schrier M.B.A.
    VP of Marketing
  • Ms. Christine Blodgett
    VP of HR
  • Dr. Julia G. Butchko Ph.D. (Age 52)
    Chief Devel. Officer













IMVT Stock - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMVT shares.
View IMVT analyst ratings
or view top-rated stocks.

What is Immunovant's stock price forecast for 2023?

12 Wall Street analysts have issued 12-month price targets for Immunovant's shares. Their IMVT share price forecasts range from $5.00 to $34.00. On average, they expect the company's stock price to reach $27.92 in the next twelve months. This suggests a possible upside of 36.9% from the stock's current price.
View analysts price targets for IMVT
or view top-rated stocks among Wall Street analysts.

How have IMVT shares performed in 2023?

Immunovant's stock was trading at $17.75 at the start of the year. Since then, IMVT shares have increased by 14.9% and is now trading at $20.39.
View the best growth stocks for 2023 here
.

Are investors shorting Immunovant?

Immunovant saw a increase in short interest in August. As of August 31st, there was short interest totaling 4,900,000 shares, an increase of 28.6% from the August 15th total of 3,810,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is currently 4.3 days. Approximately 9.3% of the company's stock are short sold.
View Immunovant's Short Interest
.

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023.
View our IMVT earnings forecast
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.03.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Deep Track Capital LP (4.15%), BlackRock Inc. (3.22%), State Street Corp (2.48%), Perceptive Advisors LLC (1.93%), Geode Capital Management LLC (0.90%) and Commodore Capital LP (0.69%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends
.

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $20.39.

How much money does Immunovant make?

Immunovant (NASDAQ:IMVT) has a market capitalization of $2.66 billion. The company earns $-210,960,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Immunovant have?

The company employs 164 workers across the globe.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The official website for the company is www.immunovant.com. The company can be reached via phone at 917-580-3099 or via email at info@immunovant.com.

This page (NASDAQ:IMVT) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -